The Nanotechnology Drug Delivery Market was valued at USD 96.39 billion in 2024 and is projected to reach USD 200.77 billion by 2032, with a CAGR of 9.56%. Nanotechnology-based systems are improving targeted drug delivery and reducing toxicity, reshaping treatment pathways in oncology, neurology, infectious diseases, and chronic conditions.

The United States leads the market, valued at USD 29.32 billion in 2024 and expected to reach USD 59.66 billion by 2032, with a CAGR of 9.24%. Strong academic research, government investment, and adoption of advanced drug delivery technologies drive growth in the US market.

In 2024, Nanoparticles dominated the market with a 49.10% share, while the oncology and Hematology segment led in revenue generation with a 33.5% market share. Biopharmaceutical companies held a 42.25% market share, and research institutes & laboratories are the fastest-growing segment.

North America held a 41.03% market share in 2024, while Asia Pacific is the fastest-growing region with a 9.81% CAGR. Sophisticated healthcare infrastructure and high investments in nanomedicine drive market dominance in North America, while Asia Pacific benefits from increased healthcare expenditure and government support for nanotechnology research.

Roche’s merger with Poseida Therapeutics for USD 1.0 billion enhances its position in CAR‑T cell therapies. The report provides insights on nanotechnology drug delivery candidates, regulatory compliance, product launches, funding trends, and competitive analysis in the market.

The Nanotechnology Drug Delivery Market is set to reach USD 200.77 billion by 2032, with a CAGR of 9.56% from 2025 to 2032. Key segments include technology (Nanoparticles, Liposomes), application (Oncology, Neurology), and end-user (Biopharmaceutical companies, Research institutes). Regional coverage includes North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

Read more at GlobeNewswire: Nanotechnology Drug Delivery Market Projected to Reach USD